Human Papillomavirus (HPV) Testing - Global Market Trajectory & Analytics

Global Human Papillomavirus (HPV) Testing Market to Reach $1.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Human Papillomavirus (HPV) Testing estimated at US$708.1 Million in the year 2020, is projected to reach a revised size of US$1.1 Billion by 2027, growing at a CAGR of 6.2% over the period 2020-2027.



The U.S. Market is Estimated at $209 Million, While China is Forecast to Grow at 5.8% CAGR

The Human Papillomavirus (HPV) Testing market in the U.S. is estimated at US$209 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$189.3 Million by the year 2027 trailing a CAGR of 5.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 5.8% and 5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Select Competitors (Total 46 Featured):

• Abbott Laboratories
• Agilent Technologies, Inc.
• Arbor Vita Corporation
• Becton, Dickinson & Company
• Cepheid, Inc.
• Daan Gene Co., Ltd.
• Diagcor Bioscience Incorporation Ltd.
• Enzo Biochem, Inc.
• F. Hoffmann-La Roche AG
• Fujirebio US, Inc.
• Greiner Bio-One International GmbH
• Hologic, Inc.
• Hybribio Limited
• Medical & Biological Laboratories Co. Ltd.
• Norgen Biotek Corporation
• Promega Corporation
• Qiagen NV
• Seegene, Inc.
• Takara Bio, Inc.
• Thermo Fisher Scientific, Inc.
• Zytovision GmbH